Literature DB >> 2624923

Distribution of radiolabelled monoclonal antibody Po66 after intravenous injection into nude mice bearing human lung cancer grafts.

B Desrues1, B Collet, M P Ramé, D Bourel, P Bourguet, A Martin, P Delaval, L Toujas, L Dazord.   

Abstract

Monoclonal antibody Po66, produced by immunization against a patient's lung squamous cell carcinoma was found suitable for the scintigraphic detection of human tumours. Surprisingly, the cellular antigen recognized by Po66 was abundant in the cytoplasm of tumour cells but could not be detected on the surface membrane. In the present work the biodistribution of radiolabelled Po66 and of an unrelated immunoglobulin were studied comparatively after intravenous injection into nude mice bearing lung squamous cell carcinoma grafts. Radioactivity distribution among mouse organs and tumour was analysed by gamma counting and autohistoradiography. After injection, radiolabelled Po66 decreased rapidly from the blood in tumour-bearing animals whereas, in controls, it remained at a level comparable to that of the unrelated immunoglobulin. The antibody seemed slowly trapped by the tumour and, 12 days after its injection, distribution ratios between tumour and mouse organs reached values of 20-30 as against 1 in animals injected with the non-specific immunoglobulin. Autohistoradiographic investigations in the tumour confirmed the slow diffusion rate of the antibody, which remained in the vascular spaces up to the 24th hour after injection and diffused afterwards throughout the clusters of tumor cells. Furthermore, radioactivity was detected in cells which, unexpectedly, seemed morphologically unaltered. These cells, the viability of which remains to be determined, were predominant in the central area of the tumours. The results presented constitute new evidence of the ability of an in vivo injected monoclonal antibody to reach a cytoplasmic target inside non-necrotic cells and suggest that the cells permeable to the antibody might be in defective nutritional conditions.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2624923     DOI: 10.1007/bf01744897

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  17 in total

1.  The response of hypoxic B16 melanoma cells to in vivo treatment with chemotherapeutic agents.

Authors:  R P Hill; J A Stanley
Journal:  Cancer Res       Date:  1975-05       Impact factor: 12.701

2.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

3.  Tissue distribution and cellular location of the antigens recognized by human monoclonal antibodies 16.88 and 28A32.

Authors:  J J Starling; R J Cote; P Marder; M J Borowitz; D A Johnson
Journal:  Cancer Res       Date:  1988-12-15       Impact factor: 12.701

4.  Characterization of the antigen identified by Po66. A monoclonal antibody raised against a lung squamous cell carcinoma.

Authors:  A Martin; P Pellen; C Guitton; P Youinou; B Collet; B Desrues; D Bourel; L Dazord; L Toujas
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 5.  Transport of molecules in the tumor interstitium: a review.

Authors:  R K Jain
Journal:  Cancer Res       Date:  1987-06-15       Impact factor: 12.701

6.  Monoclonal antibody to an intracellular antigen images human melanoma transplants in nu/nu mice.

Authors:  S Welt; M J Mattes; R Grando; T M Thomson; R W Leonard; P B Zanzonico; R E Bigler; S Yeh; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

7.  The role of membranes in the mechanism of action of the antineoplastic agent adriamycin. Spin-labeling studies with chronically hypoxic and drug-resistant tumor cells.

Authors:  J A Siegfried; K A Kennedy; A C Sartorelli; T R Tritton
Journal:  J Biol Chem       Date:  1983-01-10       Impact factor: 5.157

8.  Dynamic interaction of 111indium-labeled monoclonal antibodies with surface antigens of solid tumors visualized in vivo by external scintigraphy.

Authors:  K M Hwang; A M Keenan; J Frincke; G David; J Pearson; R K Oldham; A C Morgan
Journal:  J Natl Cancer Inst       Date:  1986-05       Impact factor: 13.506

9.  Prolonged binding of a radiolabeled monoclonal antibody (B72.3) used for the in situ radioimmunodetection of human colon carcinoma xenografts.

Authors:  D Colcher; A M Keenan; S M Larson; J Schlom
Journal:  Cancer Res       Date:  1984-12       Impact factor: 12.701

10.  Prolonged localisation of a monoclonal antibody against CEA in a human colon tumour xenograft.

Authors:  P J Harwood; R B Pedley; J Boden; G Rawlins; C R Pentycross; G T Rogers; K D Bagshawe
Journal:  Br J Cancer       Date:  1985-11       Impact factor: 7.640

View more
  3 in total

1.  Amine-reactive dyes for dead cell discrimination in fixed samples.

Authors:  Stephen P Perfetto; Pratip K Chattopadhyay; Laurie Lamoreaux; Richard Nguyen; David Ambrozak; Richard A Koup; Mario Roederer
Journal:  Curr Protoc Cytom       Date:  2010-07

Review 2.  Human galectin-8 isoforms and cancer.

Authors:  Nathalie Bidon-Wagner; Jean-Paul Le Pennec
Journal:  Glycoconj J       Date:  2002       Impact factor: 2.916

3.  Monoclonal antibody Po66 uptake by human lung tumours implanted in nude mice: effect of co-administration with doxorubicin.

Authors:  B Desrues; H Léna; F Brichory; M P Ramée; L Toujas; P Delaval; L Dazord
Journal:  Br J Cancer       Date:  1995-11       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.